C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Monday, August 31, 2020

Detailed results from the groundbreaking Phase III DAPACKD trial showed that AstraZenecas Farxiga dapagliflozin on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular CV or renal death by co...

Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment

Monday, August 31, 2020

Vir Biotechnology Inc and GlaxoSmithKline plc announced that the first patient was dosed last week in a phase study with VIR also known as GSK a fully human antiSARSCoV Severe Acute Respiratory Syndrome coronavirus monoclonal antibody for the early...

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Saturday, August 29, 2020

Novartis today announced new Phase II data for LNP an investigational oral treatment for paroxysmal nocturnal hemoglobinuria PNH presented at the virtually held European Society for Blood and Marrow Transplantation EBMT Annual Meeting In the openlab...

Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020

Saturday, August 29, 2020

Amgen announced positive data from the HAUSERRCT Phase b study evaluating the safety and efficacy of Repatha evolocumab in pediatric patients years of age with heterozygous familial hypercholesterolemia HeFH The study showed that Repatha in combinat...

Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19

Friday, August 28, 2020

Gilead Sciences Inc announced the US Food and Drug Administration FDA expanded the Emergency Use Authorization EUA enabling use of the investigational antiviral Veklury remdesivir to treat all hospitalized patients with COVID in addition to the previ...

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

Monday, August 31, 2020

SOTIO a clinical stage immunooncology company owned by PPF Group today announced that it has acquired the rights to Unum Therapeutics BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumor...

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Monday, August 31, 2020

Oncopeptides AB publ announces that the US Food and Drug Administration FDA has granted priority review for Oncopeptides New Drug Application seeking approval of melflufen INN melphalan flufenamide in combination with dexamethasone for the treatment...

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Saturday, August 29, 2020

Fortress Biotech Inc an innovative revenuegenerating company focused on acquiring developing and commercializing or monetizing promising biopharmaceutical products and product candidates costeffectively announced that its partner company Cyprium Ther...

OS Therapies to develop BlinkBio next-generation Antibody Drug Conjugate (ADC) technology; BlinkBio CEO Colin Goddard joins OS Therapies Board

Wednesday, August 26, 2020

OS Therapies and latestage clinical research biotechnology company focused on Osteosarcoma and other solid tumors today announced the coexclusive licensing of BlinkBios novel SiLinker and Cassette Payload technologies and exclusive licensing of the B...

Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs

Thursday, August 27, 2020

Piramal Pharma Solutions a leading contract development and manufacturing organization CDMO today announced that the company will be partnering with Epirium Bio on an exclusive manufacturing relationship for new orphan drugs targeting rare diseases w...